EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Editorial Archive

Defining Success in Rare Disease Paediatric Trials

Rare diseases are often chronic conditions that begin to manifest during childhood.1 The effects of disease change everything from direct consequences of having the ...
Continue Reading →
Editorial Archive

Cell and Gene Therapies are set to Revolutionise Healthcare: Here’s How

The first chemotherapy drugs were discovered by mistake – during World War II – when humans were accidentally exposed to mustard gas. At that time, the only other tr...
Continue Reading →
Editorial Archive

Generative AI is Revolutionising Life Sciences, And We’re Just Scratching the Surface

On average, it takes about seven years to develop a new drug and bring it to market. For ambitious life science businesses, generative AI’s ability to generate insig...
Continue Reading →
Editorial Archive

Modern by (Trial) Design: Shedding Legacy EDC Systems to Gain Clinical Capacity

As trials become increasingly complex, companies share how leaving behind legacy EDC systems can save thousands of hours during study build and testing. In today'...
Continue Reading →
Modern Tools to Advance Generic Drug Development and Review
Editorial Archive

Modern Tools to Advance Generic Drug Development and Review

Generic prescription drugs that are approved by the FDA have the same high quality and strength as brand-name drugs. Likewise, the manufacturing and packaging sites f...
Continue Reading →
Gene Therapy in Rare Diseases
Editorial Archive

Gene Therapy in Rare Diseases

Many rare diseases are “monogenic” – that is, they are the consequence of a defect in a single gene. Daniel Mazzolenis and Jozsef Palatka at INC Research/inVentiv Hea...
Continue Reading →
Patient Safety Monitoring and Beyond
Editorial Archive

Patient Safety Monitoring and Beyond

Whether enabling new approaches to patient safety monitoring and clinical trials, or improving success rates for regulatory submissions, artificial intelligence (AI) ...
Continue Reading →
FDA Guidance Recommends Diversity in Clinical Trials, but Can’t Require It
Editorial Archive

FDA Guidance Recommends Diversity in Clinical Trials, but Can’t Require It

The US Food and Drug Administration (FDA) frequently stress the importance of enrolling diverse patient populations in clinical trials conducted to support product ap...
Continue Reading →
Intellectual Property Strategies ‘Crucial’ to Protecting Future of Medical Innovation
Editorial Archive

Intellectual Property Strategies ‘Crucial’ to Protecting Future of Medical Innovation

Robust intellectual property protection is essential to safeguarding the future of revolutionary biomedical innovations, which transform healthcare for millions of pe...
Continue Reading →
The Lay Summary – Remember the Reader
Editorial Archive

The Lay Summary – Remember the Reader

As part of its Clinical Trial Transparency initiative, the EMA mandated a requirement for clinical trial sponsors to prepare a summary of the results of every clinica...
Continue Reading →
Catalyst: 12th January 2026
Quotient